Mast cells have crucial roles in allergic and other inflammatory diseases. Preclinical approaches provide circumstantial evidence for mast cell involvement in many diseases, but these studies have major limitations — for example, there is still a lack of suitable mouse models for some mast cell-driven diseases such as urticaria. Some approaches for studying mast cells are invasive or can induce severe reactions, and very few mediators or receptors are specific for mast cells. Recently, several drugs that target human mast cells have been developed. These include monoclonal antibodies and small molecules that can specifically inhibit mast cell degranulation via key receptors (such as FcεRI), that block specific signal transduction pathways involved in mast cell activation (for example, BTK), that silence mast cells via inhibitory receptors (such as Siglec-8) or that reduce mast cell numbers and prevent their differentiation by acting on the mast/stem cell growth factor receptor KIT. In this Review, we discuss the existing and emerging therapies that target mast cells, and we consider how these treatments can help us to understand mast cell functions in disease.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Signal Transduction and Targeted Therapy Open Access 01 September 2022
Asthma Research and Practice Open Access 15 December 2021
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Ehrlich, P. Beiträge zur Kenntniss der Anilinfärbungen und ihrer Verwendung in der mikroskopischen Technik [German]. Archiv. f. mikrosk. Anat. 13, 263–277 (1877).
Abraham, S. N. & John, A. L. S. Mast cell-orchestrated immunity to pathogens. Nat. Rev. Immunol. 10, 440–452 (2010).
Maurer, M., Köberle, M., Metz, M. & Biedermann, T. Mast cells: promoters of health and modulators of disease. J. Allergy Clin. Immunol. 144, 1–3 (2019).
Wernersson, S. & Pejler, G. Mast cell secretory granules: armed for battle. Nat. Rev. Immunol. 14, 478–494 (2014).
Di Nardo, A., Yamasaki, K., Dorschner, R. A., Lai, Y. & Gallo, R. L. Mast cell cathelicidin antimicrobial peptide prevents invasive group A Streptococcus Infection of the skin. J. Immunol. 180, 7565–7573 (2008).
Zimmermann, C. et al. Mast cells are critical for controlling the bacterial burden and the healing of infected wounds. Proc. Natl Acad. Sci. USA 116, 20500–20504 (2019).
von Köckritz-Blickwede, M. et al. Phagocytosis-independent antimicrobial activity of mast cells by means of extracellular trap formation. Blood 111, 3070–3080 (2008).
Metz, M. et al. Mast cells can enhance resistance to snake and honeybee venoms. Science 313, 526–530 (2006).
Marichal, T. et al. A beneficial role for immunoglobulin E in host defense against honeybee venom. Immunity 39, 963–975 (2013).
Starkl, P. et al. IgE effector mechanisms, in concert with mast cells, contribute to acquired host defense against staphylococcus aureus. Immunity 53, 793–804 (2020).
Galli, S. J. & Tsai, M. IgE and mast cells in allergic disease. Nat. Med. 18, 693–704 (2012).
Soto, D., Malmsten, C., Blount, J. L., Muilenburg, D. J. & Caughey, G. H. Genetic deficiency of human mast cell α-tryptase. Clin. Exp. Allergy 32, 1000–1006 (2002).
Desai, A. et al. GATA-2-deficient mast cells limit IgE-mediated immediate hypersensitivity reactions in human subjects. J. Allergy Clin. Immunol. 144, 613–617 (2019).
Sandig, H. & Bulfone-Paus, S. TLR signaling in mast cells: common and unique features. Front. Immunol. 3, 185 (2012).
Moon, T. C. et al. Advances in mast cell biology: new understanding of heterogeneity and function. Mucosal Immunol. 3, 111–128 (2010).
Bischoff, S. C. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nat. Rev. Immunol. 7, 93–104 (2007).
Galli, S. J. et al. Approaches for analyzing the roles of mast cells and their proteases in vivo. Adv. Immunol. 126, 45–127 (2015).
Luo, Y. et al. Chymase-Cre; Mcl-1fl/fl mice exhibit reduced numbers of mucosal mast cells. Front. Immunol. 10, 2399 (2019).
Dahlin, J. S. et al. The ingenious mast cell: contemporary insights into mast cell behavior and function. Allergy https://doi.org/10.1111/all.14881 (2021).
Maurer, M. et al. Mast cells drive IgE-mediated disease but might be bystanders in many other inflammatory and neoplastic conditions. J. Allergy Clin. Immunol. 144, 19–30 (2019).
Feyerabend, T. B. et al. Cre-mediated cell ablation contests mast cell contribution in models of antibody- and T cell-mediated autoimmunity. Immunity 35, 832–844 (2011).
Ghouse, S. M. et al. Although abundant in tumor tissue, mast cells have no effect on immunological micro-milieu or growth of HPV-induced or transplanted tumors. Cell Rep. 22, 27–35 (2018).
Gutierrez, DarioA. et al. Hematopoietic Kit deficiency, rather than lack of mast cells, protects mice from obesity and insulin resistance. Cell Metab. 21, 678–691 (2015).
Gaudenzio, N., Marichal, T., Galli, S. J. & Reber, L. L. Genetic and imaging approaches reveal pro-inflammatory and immunoregulatory roles of mast cells in contact hypersensitivity. Front. Immunol. 9, 1275 (2018).
Mencarelli, A. et al. A humanized mouse model to study mast cells mediated cutaneous adverse drug reactions. J. Leukoc. Biol. 107, 797–807 (2020).
Dispenza, M. C. et al. Bruton’s tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis. J. Clin. Invest. 130, 4759–4770 (2020).
Walsh, N. C. et al. Humanized mouse models of clinical disease. Annu. Rev. Pathol. 12, 187–215 (2017).
Kuehn, H. S., Radinger, M. & Gilfillan, A. M. Measuring mast cell mediator release. Curr. Protoc. Immunol. https://doi.org/10.1002/0471142735.im0738s91 (2010).
Wolf, K. et al. A group of cationic amphiphilic drugs activates MRGPRX2 and induces scratching behavior in mice. J. Allergy Clin. Immunol. 148, 506–522 (2021).
McNeil, B. D. et al. Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions. Nature 519, 237–241 (2015).
Fujisawa, D. et al. Expression of Mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria. J. Allergy Clin. Immunol. 134, 622–633 (2014). This study reveals the importance of the MRGPRX2 pathway for mast cell activation in patients with CSU, thus suggesting a novel therapeutic angle in mast cell-driven diseases.
Baumann, K. Y. et al. Skin microdialysis: methods, applications and future opportunities — an EAACI position paper. Clin. Transl. Allergy 9, 24 (2019).
John, L. M. et al. In vitro prediction of in vivo pseudo-allergenic response via MRGPRX2. J. Immunotoxicol. 18, 30–36 (2021).
Ribatti, D. The staining of mast cells: a historical overview. Int. Arch. Allergy Immunol. 176, 55–60 (2018).
Orban, N. T., Jacobson, M. R., Nouri-Aria, K. T., Durham, S. R. & Eifan, A. O. Repetitive nasal allergen challenge in allergic rhinitis: priming and TH2-type inflammation but no evidence of remodelling. Clin. Exp. Allergy 51, 329–338 (2021).
Magerl, M. et al. Critical temperature threshold measurement for cold urticaria: a randomized controlled trial of H1-antihistamine dose escalation. Br. J. Dermatol. 166, 1095–1099 (2012).
Krause, K., Spohr, A., Zuberbier, T., Church, M. K. & Maurer, M. Up-dosing with bilastine results in improved effectiveness in cold contact urticaria. Allergy 68, 921–928 (2013).
Kröger, M. et al. In vivo non-invasive staining-free visualization of dermal mast cells in healthy, allergy and mastocytosis humans using two-photon fluorescence lifetime imaging. Sci. Rep. 10, 14930 (2020).
Baumann, R. et al. Noninvasive and minimally invasive techniques for the diagnosis and management of allergic diseases. Allergy 76, 1010–1023 (2021).
Metcalfe, D. D. et al. Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases. World Allergy Organ. J. 9, 7–7 (2016).
Lyons, J. J. et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat. Genet. 48, 1564–1569 (2016).
Kolmert, J. et al. Urinary leukotriene E4 and prostaglandin D2 metabolites increase in adult and childhood severe asthma characterized by type 2 inflammation. a clinical observational study. Am. J. Respir. Crit. Care Med. 203, 37–53 (2021).
Butterfield, J. H. Increased leukotriene E4 excretion in systemic mastocytosis. Prostaglandins Other Lipid Mediat. 92, 73–76 (2010).
Jarjour, N. N., Calhoun, W. J., Schwartz, L. B. & Busse, W. W. Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with increased airway obstruction. Am. Rev. Respir. Dis. 144, 83–87 (1991).
Mersha, T. B. et al. Resolving clinical phenotypes into endotypes in allergy: molecular and omics approaches. Clin. Rev. Allergy Immunol. 60, 200–219 (2021).
Thangam, E. B. et al. The role of histamine and histamine receptors in mast cell-mediated allergy and inflammation: the hunt for new therapeutic targets. Front. Immunol. 9, 1873 (2018).
Maul, J.-T. et al. Canakinumab lacks efficacy in treating adult patients with moderate to severe chronic spontaneous urticaria in a phase II randomized double-blind placebo-controlled single-center study. J. Allergy Clin. Immunol. Pract. 9, 463–468 (2021).
Maurer, M. et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N. Engl. J. Med. 368, 924–935 (2013). This key study demonstrates omalizumab efficacy in patients with antihistamine-resistant CSU and highlights the importance of IgE–FcεRI-driven mast cell activation in this disease.
Maurer, M. et al. Ligelizumab for chronic spontaneous urticaria. N. Engl. J. Med. 381, 1321–1332 (2019). This study shows, for the first time, the high therapeutic potential of ligelizumab in CSU and its superiority over omalizumab.
Metz, M. et al. Fenebrutinib in refractory chronic spontaneous urticaria. Allergy 75, 108–110 (2020).
Youngblood, B. A. et al. AK002, a humanized sialic acid-binding immunoglobulin-like lectin-8 antibody that induces antibody-dependent cell-mediated cytotoxicity against human eosinophils and inhibits mast cell-mediated anaphylaxis in mice. Int. Arch. Allergy Immunol. 180, 91–102 (2019).
Kerr, S. C. et al. An anti-Siglec-8 antibody depletes sputum eosinophils from asthmatic subjects and inhibits lung mast cells. Clin. Exp. Allergy 50, 904–914 (2020).
Schanin, J. et al. A monoclonal antibody to Siglec-8 suppresses non-allergic airway inflammation and inhibits IgE-independent mast cell activation. Mucosal Immunol. 14, 366–376 (2021). This study demonstrates the ability of anti-Siglec-8 antibody to diminish airway inflammation and IgE-independent mast cell activation.
Zuberbier, T. et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy 73, 1393–1414 (2018).
Brightling, C. E. et al. Mast-cell infiltration of airway smooth muscle in asthma. N. Engl. J. Med. 346, 1699–1705 (2002).
Bradding, P. et al. Immunolocalization of cytokines in the nasal mucosa of normal and perennial rhinitic subjects. The mast cell as a source of IL-4, IL-5, and IL-6 in human allergic mucosal inflammation. J. Immunol. 151, 3853–3865 (1993).
Damsgaard, T. E., Olesen, A. B., Sørensen, F. B., Thestrup-Pedersen, K. & Schiøtz, P. O. Mast cells and atopic dermatitis. Stereological quantification of mast cells in atopic dermatitis and normal human skin. Arch. Dermatol. Res. 289, 256–260 (1997).
Begueret, H. et al. Inflammation of bronchial smooth muscle in allergic asthma. Thorax 62, 8–15 (2007).
Maun, H. R. et al. An allosteric anti-tryptase antibody for the treatment of mast cell-mediated severe asthma. Cell 179, 417–431.e19 (2019).
Hinks, T. S. C. et al. Innate and adaptive T cells in asthmatic patients: relationship to severity and disease mechanisms. J. Allergy Clin. Immunol. 136, 323–333 (2015).
Aguilera-Lizarraga, J. et al. Local immune response to food antigens drives meal-induced abdominal pain. Nature 590, 151–156 (2021).
Toms, R., Weiner, H. L. & Johnson, D. Identification of IgE-positive cells and mast cells in frozen sections of multiple sclerosis brains. J. Neuroimmunol. 30, 169–177 (1990).
Crisp, A. J., Chapman, C. M., Kirkham, S. E., Schiller, A. L. & Krane, S. M. Articular mastocytosis in rheumatoid arthritis. Arthritis Rheum. 27, 845–851 (1984).
Zebrowska, A. et al. Mediators of mast cells in bullous pemphigoid and dermatitis herpetiformis. Med. Inflamm. 2014, 936545 (2014).
Komi, D. E. A. & Redegeld, F. A. Role of mast cells in shaping the tumor microenvironment. Clin. Rev. Allergy Immunol. 58, 313–325 (2020).
Bieber, K. et al. Analysis of serum markers of cellular immune activation in patients with bullous pemphigoid. Exp. Derm. 26, 1248–1252 (2017).
van Nieuwenhuijze, A. E., Cauwe, B., Klatt, D., Humblet-Baron, S. & Liston, A. Lpr-induced systemic autoimmunity is unaffected by mast cell deficiency. Immunol. Cell Biol. 93, 841–848 (2015).
Inaba, Y. et al. Severer lupus erythematosus-like skin lesions in MRL/lpr mice with homozygous Kitwsh/wsh mutation. Mod. Rheumatol. 28, 319–326 (2018).
Gutierrez, D. A. et al. Type 1 diabetes in NOD mice unaffected by mast cell deficiency. Diabetes 63, 3827–3834 (2014).
Marichal, T., Tsai, M. & Galli, S. J. Mast cells: potential positive and negative roles in tumor biology. Cancer Immunol. Res. 1, 269–279 (2013).
Welsh, T. J. et al. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J. Clin. Oncol. 23, 8959–8967 (2005).
Bousquet, J. et al. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J. Allergy Clin. Immunol. 145, 70–80 (2020).
Liu, C. et al. Cloning and pharmacological characterization of a fourth histamine receptor (H4) expressed in bone marrow. Mol. Pharmacol. 59, 420–426 (2001).
Murata, Y. et al. Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis. J. Dermatol. 42, 129–139 (2015).
Kollmeier, A. P. et al. A phase 2a study of toreforant, a histamine H4 receptor antagonist, in eosinophilic asthma. Ann. Allergy Asthma Immunol. 121, 568–574 (2018).
Werfel, T. et al. Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis. J. Allergy Clin. Immunol. 143, 1830–18374 (2019).
Maun, H. R. et al. Bivalent antibody pliers inhibit β-tryptase by an allosteric mechanism dependent on the IgG hinge. Nat. Commun. 11, 6435 (2020).
Oliver, E. T. et al. Effects of an oral CRTh2 antagonist (AZD1981) on eosinophil activity and symptoms in chronic spontaneous urticaria. Int. Arch. Allergy Immunol. 179, 21–30 (2019).
Brightling, C. E. et al. Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials. Lancet Respir. Med. 9, 43–56 (2021).
Asano, K. et al. A phase 2a study of DP2 antagonist GB001 for asthma. J. Allergy Clin. Immunol. Pract. 8, 1275–1283 (2020).
Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention www.ginasthma.org (2021).
Wollenberg, A. et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J. Eur. Acad. Derm. Venereol. 32, 850–878 (2018).
Okayama, Y. et al. IgE-dependent expression of mRNA for IL-4 and IL-5 in human lung mast cells. J. Immunol. 155, 1796–1808 (1995).
Simpson, E. L. et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N. Engl. J. Med. 375, 2335–2348 (2016). This study shows that, in two phase III studies, dupilumab improved symptoms of moderate to severe atopic dermatitis, concomitant anxiety and depression, and quality of life.
Beck, L. A. et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N. Engl. J. Med. 371, 130–139 (2014). This paper reports marked and rapid effects of dupilumab in atopic dermatitis disease activity, indicating involvement of IL-4 and IL-13 in disease pathogenesis.
Castro, M. et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N. Engl. J. Med. 378, 2486–2496 (2018).
Lee, J. K. & Simpson, R. S. Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria. J. Allergy Clin. Immunol. Pract. 7, 1659–1661 (2019).
Chiricozzi, A. et al. Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo. J. Am. Acad. Dermatol. 83, 39–45 (2020).
Hanania, N. A. et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir. Med. 4, 781–796 (2016).
Panettieri, R. A. Jr et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Resp. Med. 6, 511–525 (2018).
Wollenberg, A. et al. Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb. J. Allergy Clin. Immunol. 143, 135–141 (2019).
Guttman-Yassky, E. et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol. 156, 411–420 (2020).
Castro, M. et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir. Med. 3, 355–366 (2015).
Ortega, H. G. et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 371, 1198–1207 (2014).
Harrison, T. W. et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Resp. Med. 9, 260–274 (2021). This recently published phase IIIb study in patients with severe asthma shows early benefits of benralizumab in patient-reported outcomes and lung function.
Castro, M. et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir. Med. 2, 879–890 (2014).
Haldar, P. et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med. 360, 973–984 (2009).
Bernstein, J. A. et al. Benralizumab for chronic spontaneous urticaria. N. Engl. J. Med. 383, 1389–1391 (2020). This clinical study is the first to show that benralizumab can be effective in patients with antihistamine-resistant CSU, supporting the investigation of this treatment approach in mast cell-driven diseases.
Kenna, T. J. & Brown, M. A. The role of IL-17-secreting mast cells in inflammatory joint disease. Nat. Rev. Rheumatol. 9, 375–379 (2013).
Tu, J.-F. et al. Mast cells comprise the major of interleukin 17-producing cells and predict a poor prognosis in hepatocellular carcinoma. Medicine 95, e3220 (2016).
Sabag, D. A. et al. Interleukin-17 is a potential player and treatment target in severe chronic spontaneous urticaria. Clin. Exp. Allergy 50, 799–804 (2020).
Busse, W. W. et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am. J. Respir. Crit. Care Med. 188, 1294–1302 (2013).
Silverberg, J. I. et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J. Allergy Clin. Immunol. 145, 173–182 (2020).
Kabashima, K., Matsumura, T., Komazaki, H. & Kawashima, M. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N. Engl. J. Med. 383, 141–150 (2020).
Ruzicka, T. et al. Anti-interleukin-31 receptor a antibody for atopic dermatitis. N. Engl. J. Med. 376, 826–835 (2017).
Ständer, S. et al. Trial of nemolizumab in moderate-to-severe prurigo nodularis. N. Engl. J. Med. 382, 706–716 (2020).
Busse, W. W. et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N. Engl. J. Med. 364, 1005–1015 (2011). This trial in children, adolescents and young adults with persistent allergic asthma shows that omalizumab reduced exacerbation rates and improved asthma control when added to guideline-based therapy.
Maurer, M. et al. Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase. J. Allergy Clin. Immunol. 128, 202–209 (2011).
Okayama, Y. et al. Roles of omalizumab in various allergic diseases. Allergol. Int. 69, 167–177 (2020).
Carter, M. C. et al. A randomized double-blind, placebo-controlled study of omalizumab for idiopathic anaphylaxis. J. Allergy Clin. Immunol. 147, 1004–1010.e2 (2021).
Gasser, P. et al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat. Commun. 11, 165 (2020).
Pennington, L. F. et al. Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange. Nat. Commun. 7, 11610 (2016).
Cruse, G. et al. Exon skipping of FcεRIβ eliminates expression of the high-affinity IgE receptor in mast cells with therapeutic potential for allergy. Proc. Natl Acad. Sci. USA 113, 14115–14120 (2016).
Corren, J. et al. Tezepelumab in adults with uncontrolled asthma. N. Engl. J. Med. 377, 936–946 (2017). This study shows that tezepelumab reduces exacerbation rates in patients with asthma independent of baseline blood eosinophil counts, highlighting the potential advantage of targeting upstream cytokines.
Simpson, E. L. et al. Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: a randomized phase 2a clinical trial. J. Am. Acad. Dermatol. 80, 1013–1021 (2019).
Chinthrajah, S. et al. Phase 2a randomized, placebo-controlled study of anti–IL-33 in peanut allergy. JCI Insight 4, e131347 (2019).
Chen, Y. L. et al. Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis. Sci. Transl. Med. 11, eaax2945 (2019).
Holgado, A. et al. IL-33trap is a novel IL-33-neutralizing biologic that inhibits allergic airway inflammation. J. Allergy Clin. Immunol. 144, 204–215 (2019).
Ballantyne, S. J. et al. Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. J. Allergy Clin. Immunol. 120, 1324–1331 (2007).
Tatemoto, K. et al. Endogenous protein and enzyme fragments induce immunoglobulin E-independent activation of mast cells via a G protein-coupled receptor, MRGPRX2. Scand. J. Immunol. 87, e12655 (2018).
Meixiong, J. et al. Activation of mast-cell-expressed Mas-related G-protein-coupled receptors drives non-histaminergic itch. Immunity 50, 1163–1171 (2019).
Chompunud Na Ayudhya, C., Roy, S., Alkanfari, I., Ganguly, A. & Ali, H. Identification of gain and loss of function missense variants in MRGPRX2’s transmembrane and intracellular domains for mast cell activation by substance P. Int. J. Mol. Sci. 20, 5247 (2019).
Borici-mazi, R., Kouridakis, S. & Kontou-fili, K. Cutaneous responses to substance P and calcitonin gene-related peptide in chronic urticaria: the effect of cetirizine and dimethindene. Allergy 54, 46–56 (1999).
Ogasawara, H., Furuno, M., Edamura, K. & Noguchi, M. Novel MRGPRX2 antagonists inhibit IgE-independent activation of human umbilical cord blood-derived mast cells. J. Leukoc. Biol. 106, 1069–1077 (2019).
Suzuki, Y. et al. A novel MRGPRX2-targeting antagonistic DNA aptamer inhibits histamine release and prevents mast cell-mediated anaphylaxis. Eur. J. Pharmacol. 878, 173104 (2020).
Plum, T. et al. Human mast cell proteome reveals unique lineage, putative functions, and structural basis for cell ablation. Immunity 52, 404–416 (2020).
Werfel, T., Oppermann, M., Begemann, G., Götze, O. & Zwirner, J. C5a receptors are detectable on mast cells in normal human skin and in psoriatic plaques but not in weal and flare reactions or in uticaria pigmentosa by immunohistochemistry. Arch. Dermatol. Res. 289, 83–86 (1997).
Ferrer, M., Nakazawa, K. & Kaplan, A. P. Complement dependence of histamine release in chronic urticaria. J. Allergy Clin. Immunol. 104, 169–172 (1999).
Bradding, P. & Arthur, G. Mast cells in asthma — state of the art. Clin. Exp. Allergy 46, 194–263 (2016).
Molina, C. R. et al. GSK2646264, a spleen tyrosine kinase inhibitor, attenuates the release of histamine in ex vivo human skin. Br. J. Pharmacol. 176, 1135–1142 (2019).
Dickson, M. C. et al. Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: results of a phase 1a/b randomised double-blind placebo-controlled study. Br. J. Clin. Pharmacol. https://doi.org/10.1111/bcp.14923 (2021).
Meltzer, E. O., Berkowitz, R. B. & Grossbard, E. B. An Intranasal syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J. Allergy Clin. Immunol. 115, 791–796 (2005).
Dispenza, M. C., Pongracic, J. A., Singh, A. M. & Bochner, B. S. Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy. J. All. Clin. Immunol. 141, 1914–1916 (2018).
Karra, L., Berent-Maoz, B., Ben-Zimra, M. & Levi-Schaffer, F. Are we ready to downregulate mast cells? Curr. Opin. Immunol. 21, 708–714 (2009).
Dellon, E. S. et al. Anti-Siglec-8 antibody for eosinophilic gastritis and duodenitis. N. Engl. J. Med. 383, 1624–1634 (2020). In this study, lirentelimab decreases both blood eosinophils and gastrointestinal mast cell counts in patients with eosinophilic gastritis and duodenitis, pointing to the possible contribution of mast cells to the pathogenesis of these disorders.
Bachelet, I., Munitz, A. & Levi-Schaffer, F. Abrogation of allergic reactions by a bispecific antibody fragment linking IgE to CD300a. J. Allergy Clin. Immunol. 117, 1314–1320 (2006).
Bachelet, I., Munitz, A., Berent-Maoz, B., Mankuta, D. & Levi-Schaffer, F. Suppression of normal and malignant kit signaling by a bispecific antibody linking kit with CD300a. J. Immunol. 180, 6064–6069 (2008).
Zhu, D., Kepley, C. L., Zhang, M., Zhang, K. & Saxon, A. A novel human immunoglobulin Fcγ–Fcε bifunctional fusion protein inhibits FcεRI-mediated degranulation. Nat. Med. 8, 518 (2002).
Eggel, A. et al. Inhibition of ongoing allergic reactions using a novel anti-IgE DARPin–Fc fusion protein. Allergy 66, 961–968 (2011).
Kim, B. et al. Accelerated disassembly of IgE:receptor complexes by a disruptive macromolecular inhibitor. Nature 491, 613–617 (2012).
DeAngelo, D. J. et al. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia 32, 470–478 (2018).
Valent, P. et al. Midostaurin: a magic bullet that blocks mast cell expansion and activation. Ann. Oncol. 28, 2367–2376 (2017).
Gotlib, J. et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N. Engl. J. Med. 374, 2530–2541 (2016). This phase II study provides initial evidence for the efficacy of midostaurin in patients with advanced systemic mastocytosis, including mast cell leukaemia.
Hochhaus, A. et al. Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study. J. Cancer Res. Clin. Oncol. 141, 2047–2060 (2015).
Verstovsek, S. et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin. Cancer Res. 14, 3906–3915 (2008).
Paul, C. et al. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study. Am. J. Hematol. 85, 921–925 (2010).
Lortholary, O. et al. Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study. Lancet 389, 612–620 (2017).
Smith, B. D. et al. Ripretinib (DCC-2618) is a switch control kinase inhibitor of a broad spectrum of oncogenic and drug-resistant KIT and PDGFRA variants. Cancer Cell 35, 738–751.e9 (2019).
Cahill, K. N. et al. KIT inhibition by imatinib in patients with severe refractory asthma. N. Engl. J. Med. 376, 1911–1920 (2017). This proof-of-principle trial demonstrates the association between antagonism of KIT, decreases in mast cell numbers and tryptase levels induced by imatinib with a decrease in airway hyperresponsiveness in patients with poorly controlled severe asthma.
Chanez, P. et al. Masitinib significantly decreases the rate of asthma exacerbations in patients with severe asthma uncontrolled by oral corticosteroids: a phase 3 multicenter study. Am. J. Respir. Crit. Care Med. 201, A4210 (2020).
Gotlib, J. et al. Pure pathologic response is associated with improved overall survival in patients with advanced systemic mastocytosis receiving avapritinib in the phase I EXPLORER study. Blood 136, 37–38 (2020).
Valent, P., Akin, C. & Metcalfe, D. D. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood 129, 1420–1427 (2017).
P.K. was recently a speaker for Novartis and Roche. M.Me. was recently a speaker and/or adviser for Amgen, Aralez, ArgenX, Bayer, Beiersdorf, Celgene, Galderma, Menlo, Moxie, Novartis, Roche, Sanofi, Shire, Siennabio and Uriach. F.S. was recently a speaker and/or adviser for and/or has received research funding from Allakos, Blueprint, Celldex, Genentech, Novartis, Moxie and Uriach. M.Ma. was recently a speaker and/or adviser for and/or has received research funding from Allakos, Alnylam, Amgen, Aralez, ArgenX, AstraZeneca, BioCryst, Blueprint, Celldex, Centogene, CSL Behring, Dyax, FAES, Genentech, GIInnovation, Innate Pharma, Kalvista, Kyowa Kirin, Leo Pharma, Lilly, Menarini, Moxie, Novartis, Pharming, Pharvaris, Roche, Sanofi/Regeneron, Shire/Takeda, Third HarmonicBio, UCB and Uriach. D.E.-A.-K. declares no competing interests.
Peer review information
Nature Reviews Immunology thanks P. Bradding and the other, anonymous, reviewers for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- Type I hypersensitivity
An IgE and mast cell-mediated allergic reaction in response to environmental antigens (allergens) in sensitized individuals.
A mediator stored in mast cell granules, the release of which is measured in mast cell supernatants in vitro in order to determine the degree of cell activation and degranulation upon stimulation with various substances, such as drugs or neuropeptides.
A recombinant, human anti-IL-1β mAb, approved by the FDA (US Food and Drug Administration) for the treatment of periodic fever syndromes and active systemic juvenile idiopathic arthritis.
- Bullous pemphigoid
A chronic autoimmune skin disease characterized by the production of autoantibodies against hemidesmosomal antigens, leading to the formation of subepidermal blisters.
About this article
Cite this article
Kolkhir, P., Elieh-Ali-Komi, D., Metz, M. et al. Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases. Nat Rev Immunol 22, 294–308 (2022). https://doi.org/10.1038/s41577-021-00622-y
Signal Transduction and Targeted Therapy (2022)
Nature Reviews Disease Primers (2022)
Asthma Research and Practice (2021)